

4-Aminobenzoic acid–nicotinic acid (2/1)

Samuel Robinson Jebas and
Thailampillai Balasubramanian*Department of Physics, National Institute of
Technology, Tiruchirappalli 620 015, India

Correspondence e-mail: bala@nitt.edu

In the title compound, $2C_7H_7NO_2 \cdot C_6H_5NO_2$, the 4-aminobenzoic acid and the nicotinic acid molecules are approximately planar. The crystal structure is stabilized by an extensive network of $N-H \cdots O$, $O-H \cdots O$ and $O-H \cdots N$ hydrogen bonds.

Received 24 October 2006
Accepted 6 November 2006


Key indicators

Single-crystal X-ray study
 $T = 303$ K
 Mean $\sigma(C-C) = 0.011$ Å
 R factor = 0.075
 wR factor = 0.234
 Data-to-parameter ratio = 6.2

For details of how these key indicators were automatically derived from the article, see <http://journals.iucr.org/e>.

Comment

4-Aminobenzoic acid is involved in the biosynthesis of folic acid, which is a constituent of the vitamin B complex and is found in animal and plant tissues (Zoroddu *et al.*, 1996). Nicotinic acid (vitamin B3), known as niacin, is a lipid-lowering agent widely used to treat hypertriglyceridemia by the inhibition of lipolysis in adipose tissue (Athimoolam & Rajaram, 2005). The nicotinic acid complex 5-methylpyrazine-2-carboxylic acid 4-oxide is a commonly used drug for the treatment of hypercholesterolemia (Lorenzen *et al.*, 2001). Coordination complexes of nicotinic acid with metals such as Sn possess antitumour activity greater than that of the well known *cis*-platin or doxorubicin (Gielen *et al.*, 1992). The enzyme nicotinic acid mononucleotide adenylyltransferase is essential for the synthesis of nicotinamide adenine dinucleotide in all living cells and is a potential target for antibiotics (Kim *et al.*, 2004). As a part of our investigation of interactions between acids, we report here the crystal structure of 4-aminobenzoic acid–nicotinic acid (2/1), (I).



The asymmetric unit of (I) contains two independent aminobenzoic acid molecules and a nicotinic acid molecule. The bond lengths and angles of the nicotinic acid are normal (Kutoglu & Scheringer, 1983). The nicotinic acid molecule is




Figure 1

The asymmetric unit of (I), showing the atom-numbering scheme. Displacement ellipsoids are drawn at the 50% probability level. Hydrogen bonds are shown as dashed lines.




Figure 2

A packing diagram for (I), viewed down the *b* axis. Hydrogen bonds are shown as dashed lines.

approximately planar, with a maximum deviation from the mean plane of 0.138 (4) Å for atom O6. Each of the 4-aminobenzoic acid molecules is almost planar, the maximum deviation from the mean planes being 0.077 (5) Å for atom O2 and 0.077 (5) Å for atom O3. The bond lengths and angles of *p*-aminobenzoic acid in (I) are similar to those reported for 4-aminobenzoic acid (Gracin & Fischer, 2005).

The crystal structure is stabilized by N—H...O, O—H...O and O—H...N hydrogen bonds.

Experimental

Solutions of 4-aminobenzoic acid and nicotinic acid were mixed in 2:1 molar ratio in ethanol and warmed in a water bath for 2 h. Yellow crystals were obtained after two weeks *via* slow evaporation.

Crystal data

$2C_7H_7NO_2 \cdot C_6H_5NO_2$
 $M_r = 397.38$
 Monoclinic, *Cc*
 $a = 10.1803$ (4) Å
 $b = 13.8050$ (7) Å
 $c = 13.6530$ (8) Å
 $\beta = 99.680$ (4)°
 $V = 1891.46$ (16) Å³

$Z = 4$
 $D_x = 1.395$ Mg m⁻³
 Mo $K\alpha$ radiation
 $\mu = 0.11$ mm⁻¹
 $T = 303$ (2) K
 Block, yellow
 $0.4 \times 0.25 \times 0.2$ mm

Data collection

Nonius MACH3 diffractometer
 ω - 2θ scans
 Absorption correction: ψ scan
 (North *et al.*, 1968)
 $T_{\min} = 0.969$, $T_{\max} = 0.979$
 3471 measured reflections
 1614 independent reflections

1281 reflections with $I > 2\sigma(I)$
 $R_{\text{int}} = 0.043$
 $\theta_{\text{max}} = 25.0^\circ$
 3 standard reflections
 frequency: 60 min
 intensity decay: none

Refinement

Refinement on F^2
 $R[F^2 > 2\sigma(F^2)] = 0.075$
 $wR(F^2) = 0.234$
 $S = 1.05$
 1614 reflections
 262 parameters

H-atom parameters constrained
 $w = 1/[\sigma^2(F_o^2) + (0.2P)^2]$
 where $P = (F_o^2 + 2F_c^2)/3$
 $(\Delta/\sigma)_{\text{max}} = 0.006$
 $\Delta\rho_{\text{max}} = 0.33$ e Å⁻³
 $\Delta\rho_{\text{min}} = -0.30$ e Å⁻³

Table 1

Hydrogen-bond geometry (Å, °).

<i>D</i> —H... <i>A</i>	<i>D</i> —H	H... <i>A</i>	<i>D</i> ... <i>A</i>	<i>D</i> —H... <i>A</i>
O6—H6A...N3 ⁱ	0.82	1.73	2.549 (7)	177
N2—H2A...O2 ⁱⁱ	0.86	2.56	3.278 (10)	141
N2—H2B...O5 ⁱⁱⁱ	0.86	2.11	2.930 (11)	160
N1—H1A...O6 ^{iv}	0.86	2.32	3.113 (10)	154
N1—H1B...O3 ⁱ	0.86	2.57	3.303 (11)	144
O4—H4...O2	0.82	1.81	2.620 (8)	168
O1—H1...O3	0.82	1.79	2.596 (8)	167

Symmetry codes: (i) $x, -y, z - \frac{1}{2}$; (ii) $x, -y + 1, z + \frac{1}{2}$; (iii) $x, y + 1, z$; (iv) $x + \frac{1}{2}, y - \frac{1}{2}, z$.

After checking their presence in a difference map, H atoms were placed in calculated positions, with C—H = 0.93 Å, O—H = 0.82 Å and N—H = 0.82 Å, and refined using a riding model, with $U_{\text{iso}}(\text{H}) = 1.2U_{\text{eq}}(\text{C,N})$ and $1.5U_{\text{eq}}(\text{O})$. In the absence of significant anomalous scattering effects, 158 Friedel pairs were averaged.

Data collection: *CAD-4 EXPRESS* (Enraf–Nonius, 1994); cell refinement: *CAD-4 EXPRESS*; data reduction: *XCAD4* (Harms & Wocadlo, 1995); program(s) used to solve structure: *SHELXS97* (Sheldrick, 1997); program(s) used to refine structure: *SHELXL97* (Sheldrick, 1997); molecular graphics: *PLATON* (Spek, 2003); software used to prepare material for publication: *SHELXL97*.

References

- Athimoolam, S. & Rajaram, R. K. (2005). *Acta Cryst.* **E61**, o2764–o2767.
 Enraf–Nonius (1994). *CAD-4 EXPRESS*. Version 5.1/1.2. Enraf–Nonius, Delft, The Netherlands.
 Gielen, M., Khouloufi, A. E., Biesemans, M. & Willem, R. (1992). *Polyhedron*, **11**, 1861–1868.
 Gracin, S. & Fischer, A. (2005). *Acta Cryst.* **E61**, o1242–o1244.
 Harms, K. & Wocadlo, S. (1995). *XCAD4*. University of Marburg, Germany.
 Kim, H.-L., Yoon, H.-J., Ha, J. Y., Lee, B. I., Lee, H. H., Mikami, B. & Suh, S. W. (2004). *Acta Cryst.* **D60**, 948–949.
 Kutoglu, A. & Scheringer, C. (1983). *Acta Cryst.* **C39**, 232–234.
 Lorenzen, A., Stannek, C., Lang, H., Andrianov, V., Kalvinsh, I. & Schwabe, U. (2001). *Mol. Pharmacol.* **59**, 349–357.
 North, A. C. T., Phillips, D. C. & Mathews, F. S. (1968). *Acta Cryst.* **A24**, 351–359.
 Sheldrick, G. M. (1997). *SHELXL97* and *SHELXS97*. University of Göttingen, Germany.
 Spek, A. L. (2003). *J. Appl. Cryst.* **36**, 7–13.
 Zoroddu, M. A., Dallochio, R. & Mosca, S. (1996). *Polyhedron*, **15**, 277–283.